Vascular Solutions (Nasdaq: VASC) reported earnings on Oct. 18. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended Sep. 30 (Q3), Vascular Solutions met expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue grew slightly and GAAP earnings per share contracted significantly.

Margins shrank across the board.

Revenue details
 Vascular Solutions tallied revenue of $24.6 million. The five analysts polled by S&P Capital IQ foresaw a top line of $24.8 million on the same basis. GAAP reported sales were 1.0% higher than the prior-year quarter's $24.3 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.16. The four earnings estimates compiled by S&P Capital IQ forecast $0.15 per share. GAAP EPS of $0.16 for Q3 were 27% lower than the prior-year quarter's $0.22 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 66.7%, 260 basis points worse than the prior-year quarter. Operating margin was 16.9%, 540 basis points worse than the prior-year quarter. Net margin was 10.4%, 490 basis points worse than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $25.7 million. On the bottom line, the average EPS estimate is $0.17.

Next year's average estimate for revenue is $99.0 million. The average EPS estimate is $0.58.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 91 members out of 103 rating the stock outperform, and 12 members rating it underperform. Among 24 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 19 give Vascular Solutions a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Vascular Solutions is buy, with an average price target of $16.15.